{"id":477889,"date":"2021-04-19T08:03:49","date_gmt":"2021-04-19T12:03:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/"},"modified":"2021-04-19T08:03:49","modified_gmt":"2021-04-19T12:03:49","slug":"ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/","title":{"rendered":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON and HOUSTON and TAIPEI, Taiwan, April  19, 2021  (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or the \u201cCompany\u201d) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (\u201cRPM\u201d) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.<\/p>\n<p align=\"justify\">The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu.<\/p>\n<p align=\"justify\">The patient\u2019s T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company\u2019s non-viral <em>Sleeping Beauty<\/em> transposon transposase system and infused two days after gene transfer.<\/p>\n<p align=\"justify\">\u201cWe are excited to be conducting this important trial for this experimental treatment,\u201d said Dr. Jay Zhang, Chief Executive Officer of TriArm Therapeutics.<\/p>\n<p align=\"justify\">The Company and Eden BioCell will provide updates regarding the experimental treatment and other patient data in the second half of the year at appropriate venue(s), including scientific conferences, publications and \/ or bespoke events that the Company may convene.<\/p>\n<p align=\"justify\">\n        <strong>About the Trial <\/strong><br \/>\n        <strong><br \/>\n          <em>\u201cInfusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients with Advanced Lymphoid Malignancies\u201d<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>This is a single center phase I, open-label dose-escalation trial, for patients with relapsed CD19+ leukemias and lymphomas. Up to 24 patients will be enrolled in this trial. The primary endpoint of the trial is to evaluate the safety and tolerability of autologous CD19-specific T cells manufactured using the RPM process.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Ziopharm Oncology, Inc.<\/strong><br \/>\n        <br \/>Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body\u2019s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm\u2019s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral\u00a0<em>Sleeping Beauty<\/em>\u00a0gene transfer platform, a rapidly manufactured\u00a0<em>Sleeping Beauty<\/em>-enabled CD19-specific CAR-T program, and a precisely controlled IL-12 gene therapy. The Company has clinical and strategic collaborations with the\u00a0National Cancer Institute,\u00a0The University of Texas MD Anderson Cancer Center\u00a0and Regeneron Pharmaceuticals. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VgB2rHmMDwo6tbL0fH_rk2OhmoLABElH8Jm3quR9dEvMIsE1QqJ6e5BHNXdpyez9Vjwfd52SZkQV1gv7HBZBPRWKABcGuKey3BqQ1EsjP1Op5g3x5Tn2I8-SEsqGycdSUrMeuJOHSonibHh4-OTGGqap8IZxFoQ7QhbSI7sf9954LQNdJUF7x8v-JFRjFGI30e1RNnRx-vrVM59Y4BOSJ2XNUIhe4EvVQWglaZVmIE0=\" rel=\"nofollow noopener\" target=\"_blank\">www.ziopharm.com<\/a>.<\/p>\n<p>\n        <strong>About Eden BioCell<\/strong><br \/>\n        <br \/>In December 2018, Ziopharm and TriArm Therapeutics announced the launch of Eden BioCell to lead clinical development and commercialization of Ziopharm\u2019s RPM Sleeping Beauty-generated CAR-T therapies in Greater China and Korea.<\/p>\n<p>\n        <strong>About TriArm Therapeutics<\/strong><br \/>\n        <br \/>TriArm Therapeutics is a cell therapy company with R&amp;D operations in Germany, United States and Asia. The company is dedicated to the treatment of cancer and autoimmune diseases.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Adam D. Levy, Ph.D., MBA<br \/>EVP, Investor Relations and Corporate Communications<br \/>T: 508.552.9255<br \/>E:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AE6MOragV_3TU-VflPswt0Ra-g95neZOw1_2kg1a_OvELNG2xnQiuJMFgnYMkUez3tDalutiTbfLgsxouGmX2Sd-eI8p5752MGgHJ6bXjWs=\" rel=\"nofollow noopener\" target=\"_blank\">alevy@ziopharm.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements Disclaimer<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; and &#8220;believes.&#8221; These statements include, but are not limited to, statements regarding the number of patients to be enrolled, and the timing of updates for, Eden BioCell\u2019s CAR-T Phase I trial. Although Ziopharm\u2019s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in Eden BioCell\u2019s operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis; the strength and enforceability of Ziopharm\u2019s intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the\u00a0Securities and Exchange Commission\u00a0made by Ziopharm, including those risks and uncertainties listed in Ziopharm\u2019s Quarterly Report on Form 10-Q filed by Ziopharm with the\u00a0Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c1c267b2-5dc2-4b02-a3d7-7c50630768ef\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or the \u201cCompany\u201d) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (\u201cRPM\u201d) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu. The patient\u2019s T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company\u2019s non-viral Sleeping Beauty transposon transposase system and infused two days after gene transfer. \u201cWe are excited to be conducting this important trial for this experimental treatment,\u201d said Dr. Jay Zhang, Chief Executive Officer &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-477889","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or the \u201cCompany\u201d) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (\u201cRPM\u201d) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu. The patient\u2019s T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company\u2019s non-viral Sleeping Beauty transposon transposase system and infused two days after gene transfer. \u201cWe are excited to be conducting this important trial for this experimental treatment,\u201d said Dr. Jay Zhang, Chief Executive Officer &hellip; Continue reading &quot;Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T12:03:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell\",\"datePublished\":\"2021-04-19T12:03:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/\"},\"wordCount\":744,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/\",\"name\":\"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\",\"datePublished\":\"2021-04-19T12:03:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/","og_locale":"en_US","og_type":"article","og_title":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk","og_description":"BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or the \u201cCompany\u201d) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (\u201cRPM\u201d) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu. The patient\u2019s T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company\u2019s non-viral Sleeping Beauty transposon transposase system and infused two days after gene transfer. \u201cWe are excited to be conducting this important trial for this experimental treatment,\u201d said Dr. Jay Zhang, Chief Executive Officer &hellip; Continue reading \"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T12:03:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell","datePublished":"2021-04-19T12:03:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/"},"wordCount":744,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/","name":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=","datePublished":"2021-04-19T12:03:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODY2MyM0MTI1NTI0IzIwMDc1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=477889"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=477889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=477889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=477889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}